Lv41
632 积分 2024-11-04 加入
From Fragment Hit to Clinical Candidate: Discovery of Dual H1R/H4R Ligands with Superior Efficacy in Allergic Conjunctivitis
6天前
已完结
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors
6天前
已完结
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors
14天前
已完结
From Fragment Hit to Clinical Candidate: Discovery of Dual H1R/H4R Ligands with Superior Efficacy in Allergic Conjunctivitis
14天前
已完结
Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 Inhibitors
24天前
已完结
Discovery and Characterization of RP04340: A Highly Potent and Orally Active Pan-KRAS PROTAC Degrader
24天前
已完结
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
2个月前
已完结
Discovery of a Novel Ketohexokinase Inhibitor with Improved Drug Distribution in Target Tissue for the Treatment of Fructose Metabolic Disease
2个月前
已完结
Development of a novel PI3Kα/CDK7 potent hybrid inhibitor for Cancer treatment
2个月前
已完结
皖公网安备34019202002308
